Thyrocare Technologies Limited has informed the Exchange that Board of Directors at its meeting held on May 07, 2026, recommended Final Dividend of Rs. 7 per equity share.
THYROCARE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.9 pts more than Nifty Microcap 250 and 1.4 pts more than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Thyrocare Technologies' Board meeting on May 07, 2026 approved multiple items including a final dividend of Rs. 7 per equity share for FY 2025-26. Combined with the already paid interim dividend of Rs. 7 per share (pre-bonus; Rs. 2.33 post bonus adjustment), the total dividend for the year stands at Rs. 9.33 per share, subject to shareholder approval at AGM. The company also appointed Price Waterhouse Chartered Accountants LLP as new statutory auditors for 5 years, re-appointed Rahul Franklin Guha as Chairman, MD & CEO for another 5 years from May 2027, and added two new Non-Executive Directors (Uday Patel Kadam and Gaurav Verma) from API Holdings. Two directors resigned. Additionally, the Board approved investing up to Rs. 5.5 crore in Think Health Diagnostics Private Limited (a wholly owned subsidiary) and proposed amendments to the Memorandum of Association to expand the company's scope into broader healthcare and diagnostics activities.
The dividend declaration signals financial health and commitment to shareholder returns. The board changes bring experienced leadership from API Holdings (parent), potentially strengthening the PharmEasy- Thyrocare integration. The expanded MOA suggests strategic moves beyond core diagnostics into digital health platforms, equipment dealing, and wider healthcare services.